Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 28575485)

  • 1. Adult IDH wild-type lower-grade gliomas should be further stratified.
    Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
    Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
    Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data.
    Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G
    World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
    Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
    Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
    Komori T
    Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
    Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
    Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
    Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
    Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
    Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
    Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
    Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
    Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
    Rice T; Zheng S; Decker PA; Walsh KM; Bracci P; Xiao Y; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Hsuang G; Wiemels JL; Tihan T; Pico AR; Prados MD; Chang SM; Berger MS; Caron A; Fink S; Kollmeyer T; Rynearson A; Voss J; Kosel ML; Fridley BL; Lachance DH; Eckel-Passow JE; Sicotte H; O'Neill BP; Giannini C; Wiencke JK; Jenkins RB; Wrensch MR
    Neuro Oncol; 2013 May; 15(5):535-41. PubMed ID: 23361564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
    Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
    World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
    Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
    Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.